stockrow
Friday 6 November 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
- EPS
- +41.5%
- Free cash flow
- −32.7%
Quarter to June 2026, against a year earlier
10.35
0.30
+2.99%
Follow INKT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 1 | — | — | — | — | — | — | — | — | 2 | 3 | 10 | +127.1% | |
| Gross margin, % | — | — | — | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | — | — | — | (24) | (16) | (30) | (28) | (22) | (11) | (12) | (11) | (10.2%) | ||||||
| EBT margin, % | — | — | — | (3,451.60) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +3,451.6 pt | ||||||
| Net income | — | 0 | — | (24) | (16) | (30) | (28) | (22) | (11) | (12) | (11) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (9.89) | (6.74) | (11.60) | (8.30) | (6.50) | (2.86) | (2.93) | (2.40) | (18.4%) | ||||||
| Cash flow | — | — | — | (6.21) | (3.46) | (4.93) | (5.60) | (4.59) | (2.53) | (1.39) | (1.36) | (22.1%) | ||||||
| Capex | — | — | — | (0.18) | (0.04) | (0.10) | (0.07) | (0.02) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (6.39) | (3.50) | (5.02) | (5.68) | (4.61) | (2.53) | (1.39) | (1.36) | (22.5%) | ||||||
| Book value | — | — | — | (15.10) | (22.35) | 9.14 | (0.12) | (5.25) | (5.19) | (3.33) | (2.79) | (22.3%) | ||||||
| Shares, m | — | — | — | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5 | +10.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | — | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | 0.00 | — | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | 0.00 | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | — | — | — | 0.00 | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | (25.47) | — | — | — | — | — | — | (6.97) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (15) | (8) | (13) | (19) | (16) | (10) | (6) | (7) | (14.3%) | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | (35.5%) | ||||||
| Free cash flow | — | — | — | (15) | (8) | (13) | (19) | (16) | (10) | (6) | (7) | (14.7%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (7) | (10) | 23 | 8 | (8) | (2) | 1 | 2 | n/m | |||||
| Net debt | — | — | — | 26 | 41 | (39) | (20) | (3) | 0 | (13) | (9) | n/m | ||||||
| Shareholders’ equity | — | — | — | (36) | (54) | 24 | 0 | (18) | (20) | (14) | (14) | (14.5%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (3,636.98) | (553.84) | (134.89) | (90.71) | (172.59) | (209.96) | (125.20) | (187.78) | +3,511.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 52.77 | 36.00 | 200.76 | (239.49) | 243.36 | 57.30 | 73.90 | 57.94 | +21.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 31 | 33 | 37 | 31 | 23 | 15 | — | (13.5%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · fundamentals updated 25 Oct 2026
MiNK Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $52.3M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $50.5M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $49.6M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| Median of peers | $51.6M | — | — | −53.85% | — | −9.42% | 42.51% | 0.00% |